Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed ...Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.展开更多
丙型病毒性肝炎（hepatitis C virus，HCV）已经呈全球性流行，全球HCV的感染率约为3％，估计约1．7亿人已感染了HCV。我国流行病学调查资料显示，一般人群抗HCV阳性率为3．2％。维持性血液透析患者由于机体免疫功能低下、血液透析时频...丙型病毒性肝炎（hepatitis C virus，HCV）已经呈全球性流行，全球HCV的感染率约为3％，估计约1．7亿人已感染了HCV。我国流行病学调查资料显示，一般人群抗HCV阳性率为3．2％。维持性血液透析患者由于机体免疫功能低下、血液透析时频繁地体外循环和血管穿刺、反复输血和其它各种医源性因素，而成为HCV感染的高危人群。在意大利伦巴地地区透析和移植登记中心显示，1998年5633名透析患者中HCV阳性率为24．3％。埃及开罗地区的7个血液透析中心中HCV阳性率达80％。北京地区1998年225例血液透析患者中HCVRNA阳性16．4％㈨。我们报道62例血液透析患者抗HCV阳性率54．8％。血液透析患者HCV高感染率日益引起人们的关注，既往认为输血是血液透析患者感染丙型肝炎的重要原因，但是随着ELISA血清试验的推广和EPO的广泛应用，血液透析患者中输血所致的HCV明显减少，但血液透析患者中HCV发病率仍居高不下。本文就有关维持性血液透析患者HCV的院内传播途径和防治的研究进展作一综述。展开更多
文摘Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.
文摘丙型病毒性肝炎（hepatitis C virus，HCV）已经呈全球性流行，全球HCV的感染率约为3％，估计约1．7亿人已感染了HCV。我国流行病学调查资料显示，一般人群抗HCV阳性率为3．2％。维持性血液透析患者由于机体免疫功能低下、血液透析时频繁地体外循环和血管穿刺、反复输血和其它各种医源性因素，而成为HCV感染的高危人群。在意大利伦巴地地区透析和移植登记中心显示，1998年5633名透析患者中HCV阳性率为24．3％。埃及开罗地区的7个血液透析中心中HCV阳性率达80％。北京地区1998年225例血液透析患者中HCVRNA阳性16．4％㈨。我们报道62例血液透析患者抗HCV阳性率54．8％。血液透析患者HCV高感染率日益引起人们的关注，既往认为输血是血液透析患者感染丙型肝炎的重要原因，但是随着ELISA血清试验的推广和EPO的广泛应用，血液透析患者中输血所致的HCV明显减少，但血液透析患者中HCV发病率仍居高不下。本文就有关维持性血液透析患者HCV的院内传播途径和防治的研究进展作一综述。
